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Background: Vortioxetine is the first mixed serotonin agonist and antagonist antidepressant approved in the US.
We sought to evaluate all published and unpublished data available to determine the efficacy and harms of
vortioxetine in adults with major depressive disorder.
Methods: We used a predefined search strategy of MEDLINE, the Cochrane Central Register of Controlled Trials,
ClinicalTrials.gov, and Drugs@FDA to identify studies evaluating vortioxetine in the acute treatment of major
depressive disorder. Only randomized controlled trials (RCTs) that provided results on relevant clinical efficacy
and safety outcomes were included. Study quality was assessed and results were pooled using mixed effect
meta-analyses where applicable.
Results: We identified 11 RCTs with 6,145 participants meeting inclusion criteria (eight were published and three
were unpublished). The trials did not exceed 8 weeks in duration. The response rate with vortioxetine was significantly
higher for 1-mg (relative risk (RR) = 1.91; 95% confidence interval (CI) 1.36 to 2.69), 5-mg (RR = 1.33; 95% CI 1.10 to 1.61),
10-mg (RR = 1.42; 95% CI 1.21 to 1.67), and 20-mg doses (RR = 1.58; 95% CI 1.19 to 2.08) compared to placebo.
Remission rates were significantly higher for the 10-mg group (RR = 1.45; 95% CI 1.18 to 1.77) and the 20-mg
group (RR = 1.68; 95% CI 1.19 to 2.37) compared to placebo. Meta-regression of dose on the log odds ratio of
response was not statistically significant (β = 0.01; P = 0.46). Vortioxetine response rates were lower than active
serotonin and norepinephrine reuptake inhibitor (SNRI) comparators for the 5-mg (RR = 0.88; 95% CI 0.80 to 0.98),
15-mg (RR = 0.78; 95% CI 0.68 to 0.90), and 20-mg (RR = 0.82; 95% CI 0.72 to 0.94) doses. The most common
adverse events were nausea and vomiting which increased in frequency with higher doses.
Conclusions: Vortioxetine was significantly more effective than placebo for acute treatment of major depressive
disorder (MDD). Although treatment effect estimates varied substantially between studies, a dose effect was not
observed. Vortioxetine does not appear to be more effective, and is potentially less effective, than an SNRI.
Systematic review registration: PROSPERO CRD42013006198.
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Depressive disorders, including major depressive disorder
(MDD), are common mental health conditions thought to
be caused by an imbalance in serotonin (5-HT) and nor-
epinephrine in addition to multiple situational, cognitive,
and medical factors. Pharmacotherapy is commonly used* Correspondence: hartungd@ohsu.edu
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unless otherwise stated.in the medical management of depressive disorders and
may include first-generation antidepressants (tricyclic
antidepressants and monoamine oxidase inhibitors) and
second-generation antidepressants (selective serotonin re-
uptake inhibitors (SSRIs) and serotonin and norepineph-
rine reuptake inhibitors (SNRIs)). These drugs selectively
modulate neurotransmitters, including 5-HT, norepineph-
rine, and dopamine, in the central nervous system.
Current evidence suggests that most second-generation
antidepressants have similar efficacy for the treatment of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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therapy because they have a favorable risk-benefit ratio
compared to first-generation antidepressants and SNRIs
[3]. In October 2013, the US Food and Drug Administra-
tion (FDA) approved vortioxetine for the treatment of
MMD [4]. Vortioxetine has also been approved by the
European Medicines Agency (EMA). Different than other
approved SSRIs, vortioxetine is a multimodal antidepres-
sant believed to work through a mix of 5-HT agonism
and antagonism. To date, seven distinct families of 5-
HT receptors have been identified (5-HT1 to 5-HT7)
and subpopulations have been described for 5-HT1 and
5-HT2. Antidepressant activity is mediated through
agonism at 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6,
as well as antagonism at 5-HT2A, 5-HT3, and 5-HT7 [5]. In
vitro data suggest vortioxetine is an antagonist of 5-HT3,
5-HT7, and 5-HT1D; an agonist of 5-HT1A; a partial agonist
of 5-HT1B; and an inhibitor of 5-HT transporter [6].
According to the FDA label, the efficacy of vortioxetine
was demonstrated in six positive randomized clinical trials
(RCTs) of 6- to 8-weeks duration. In their review, the
FDA deemed the 20-mg dose as the most consistently
positive dosing arm. They therefore advise that patients
should be started on 10 mg/day, and the dosage should be
increased to 20 mg/day as tolerated. Because publication
bias is a well-recognized concern in the antidepressant
literature, it is unclear if these six trials represent the
entire trial program for vortioxetine [7]. To address this
uncertainty, we conducted a systematic review of pub-
lished and unpublished data to summarize the efficacy
and harms of vortioxetine for the treatment of MDD.
Methods
For this systematic review, we considered the following
questions: 1) for patients with acute MDD, what is the
efficacy of vortioxetine compared to other antidepressants
or placebo; 2) for patients with acute MDD, what are the
harms of vortioxetine compared with other antidepressants
or placebo. A structured protocol was developed a priori
(PROSPERO Registration ID: CRD42013006198). To iden-
tify relevant articles, we conducted a focused Medline and
EMBASE search through 18 September 2014 using the fol-
lowing terms: (vortioxetine) OR (Lu AA21004). Supple-
mental searches were conducted using the Cochrane
Central Register of Controlled Trials using analogous
terms. We also identified relevant studies through a review
of ClinicalTrials.gov, the FDA website (Drugs@FDA),
and requested trial information from the manufacturer
(Takeda). The citations of yielded articles were reviewed
to identify other potentially relevant studies.
Study selection
RCTs investigating the safety and efficacy of vortioxetine
for acute treatment of MDD compared to placebo oranother antidepressant were included. Only original re-
search studies that provided results on relevant clinical
outcomes in a useable format were included. There were
no limits on race, ethnicities, cultural groups, language, or
setting. Editorials, letters, and non-systematic literature
reviews were not included. Results from our search were
reviewed independently by two investigators (ASM and
DMH). Discrepancies were resolved through consensus.
Outcome measures
The primary efficacy outcomes were response and remis-
sion. Response is typically defined by a decrease of ≥50%
in the Hamilton Depression Rating Scale (HAMD) or
Montgomery-Åsberg Depression Rating Scale (MADRS)
scores from baseline [8]. Remission is defined by a total
HAMD (≤7) or MADRS (≤10) score [8]. Secondary effi-
cacy outcomes of interest were absolute change in HAMD
and MADRS scores from baseline. We also summarized
the rates of serious adverse events, common adverse
events (>5%) including nausea, diarrhea, dry mouth, and
withdrawal due to adverse events.
Data extraction
One author (ASM) extracted trial data into evidence
tables describing the population characteristics, study
subject selection and attrition, primary efficacy, and
harm findings; a second author (DMH) validated the
data. Our primary sources of data were publications. For
dichotomous outcomes, we used the reported denomin-
ator for each outcome. We also attempted to obtain data
from unpublished trials or trials with insufficiently re-
ported outcomes through examination of ClinicalTrials.
gov, Drugs@FDA, and the manufacturers’ dossier. Clini-
calTrials.gov is the largest publically accessible clinical
trial registry in the world. As of 2008, certain trials of
drugs, biologics, and devices regulated by the US FDA
are required to report summary results data in Clinical-
Trials.gov within 1 year of trial completion. Clinical-
Trials.gov’s required reporting elements include basic
demographics, all primary and secondary outcomes, and
adverse events.
Quality assessment
To assess the quality of studies, we used predefined cri-
teria based on those developed by the Pacific Northwest
Evidence-Based Practice Center Drug Effectiveness Review
Project (DERP) [9]. In general, a “good” study has the least
bias and results are considered to be valid, a “fair” study is
susceptible to some bias but probably not sufficient to in-
validate its results and a “poor” rating indicates significant
bias that may invalidate the study’s results. Three mem-
bers of the team (DMH, MCH, and ASM) independently
reviewed included papers using the DERP criteria and
assigned each study an overall quality rating. Conflicts
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studies were assessed for quality on evaluable characteris-
tics (baseline similarity among treatment groups, attrition,
and use of an intention-to-treat protocol).
Statistical analysis
Quantitative synthesis of outcomes was performed using
random effects meta-analysis. Risk ratios (relative risk
(RRs)) and 95% confidence intervals (95% confidence in-
tervals (CIs)) were calculated for dichotomous outcomes
of interest (e.g., response rates). A random effects model
using the DerSimonian and Laird method was used to
calculate for the weighted mean effect size for trials by
dosing arm. The I2 statistic was calculated to describe
the proportion of the variability that was due to hetero-
geneity rather than sampling error. We explored ob-
served heterogeneity quantitatively and qualitativelyFigure 1 PRISMA flowchart of study selection.using meta-regression and sensitivity analysis. Publica-
tion bias was evaluated using a funnel plot and Egger’s
test. Stata13™ (Stat Corp; College Station, TX) was used
to carry out all statistical analyses [10]. The findings of
this systematic review are reported according to the
guidelines of the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) [11].
Results
The literature search resulted in a total of 75 records after
duplicates were removed. Of these, 56 were excluded
because they did not meet inclusion criteria, and 19 candi-
date trials were assessed for eligibility. Eleven remaining
RCTs with a total of 6,145 patients fulfilled the inclusion
criteria (Figure 1). Of these 11 trials, eight were in peer-
reviewed publications and three were unpublished but
had results summarized in FDA review documents or
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and findings of the included studies. Trials ranged in size
from 429 to 776 participants. All trials were placebo con-
trolled; six trials also included an active comparator arm
with an SNRI (one trial included venlafaxine and five trials
included duloxetine). Several trials studied more than one
vortioxetine dose ranging from 1 to 20 mg. Five trials were
conducted within the US, four were outside the US, and
two included US and non-US sites. Of the published trials,
all but one were rated fair or good quality. The trial by
Henigsberg et al [12] was determined to be of poor quality
because it did not use an intent-to-treat analysis and sev-
eral critical trial features were not clearly described. All
unpublished studies were rated fair quality based on eva-
luable domains (intention-to-treat analysis, similar base-
line characteristics, attrition). Details of trial findings and
quality appraisal can be found in Additional file 1.
Efficacy compared to placebo
Trials used either or both of the MADRS or HAMD
scales to measure efficacy of vortioxetine. Nine trials
compared vortioxetine to placebo for response using the
MADRS scale at 6 to 8 weeks [6,12-16]. Two trials
defined response using the HAMD scale [17,18]. Three
trials assessed response with both scales [6,12,14]. For
our analysis of response, we first synthesized the MADRS
response using HAMD response for the two trials not
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V = vortioxetine; VLFX = venlafaxine XR; DLX = duloxetine; NR = not reported; NCT =
or negative by FDA; conly evaluable trial characteristics assessed.compared to placebo, response rates were significantly
higher for vortioxetine 1-mg (RR = 1.91; 95% CI 1.36 to
2.69; I2 = not applicable), 5-mg (RR = 1.33; 95% CI 1.10 to
1.61; I2 = 71%), 10-mg (RR = 1.42; 95% CI 1.21 to 1.67;
I2 = 49.3%), and 20-mg dose groups (RR = 1.58; 95% CI
1.19 to 2.08; I2 = 76.3%). Heterogeneity was very high for
most of the dose comparisons. Removing the two trials that
did not measure response using MADRS had no meaning-
ful impact on the RRs for response at any dosing level.
All 11 trials compared vortioxetine to placebo in remis-
sion based on the MADRS scale. The meta-analysis of
remission is summarized in Figure 3. Results demonstrated
a statistically significant difference in remission rates for the
10-mg (RR 1.45; 95% CI 1.18 to 1.77; I2 = 35%) and the
20-mg groups (RR 1.68; 95% CI 1.19 to 2.37; I2 = 67%)
compared to placebo, but no difference for the 1-mg
(1.57; 95% CI 0.98 to 2.50; I2 = not applicable), 2.5-mg
(RR 0.99; 95% CI 0.77 to 1.28; I2 = 0%), 5-mg (RR 1.27;
95% CI 0.98 to 1.66; I2 = 70.4%), and 15-mg groups (RR
1.26; 95% CI 0.86 to 1.84; I2 = 63.9%) compared to placebo.
There was considerable heterogeneity between trials for
each dose.
All 11 trials reported changes from baseline in the
MADRS total score. Figure 4 summarizes the synthesis
of these data by dosing level compared to placebo. Sig-
nificant reductions in MADRS compared to placebo
ranged from 2.67 (95% CI 0.83 to 4.5; I2 = 76%) for the
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43.3 34.0 8.0 62.7 6 weeks Good
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46.7 31.4 1.8 65.9 8 weeks Fair
45.7 31.5 5.5 66.2 8 weeks Good
42.9 32.1 23.4 73.8 8 weeks Fairc
42.8 32.2 30.1 72.5 8 weeks Fairc
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Figure 2 Forest plot showing response rates for vortioxetine by dose compared to placebo.
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Figure 3 Forest plot showing remission rates for vortioxetine by dose compared to placebo.































































































































Favors Placebo  Favors Vortioxetine 
0-5 5
N, difference (SD) N, difference (SD)
Placebo Vortioxetine
Figure 4 Forest plot showing change from baseline in MADRS score for vortioxetine by dose compared to placebo.
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change from baseline in the 2.5 or 15-mg dose groups.
Similar to response and remission, heterogeneity was
very high.
Table 2 summarizes meta-regressions performed in an
attempt to identify and explain trial heterogeneity. We
first examined the association between dose and response.Nine trials had more than one vortioxetine dosing arm.
For this meta-regression, we partitioned the number of
responders and denominator from the placebo arm equally
among the vortioxetine arms to avoid double counting
subjects receiving placebo [19]. For example, in the trial by
Alvarez et al. [6], 47 out of 105 subjects receiving placebo
had a response. Because the trial had two vortioxetine
Table 2 Meta-regression of study characteristics on log odds ratio for response
Variable Coefficient 95% confidence interval P value Residual I2
Dosea 0.01 −0.02 to 0.04 0.46 67%
Unpublished −0.44 −1.04 to 0.16 0.13 74%
Poor quality 0.44 −0.57 to 1.45 0.35 77%
Poor quality or unpublished study −0.23 −0.84 to 0.38 0.42 78%
Non-US-based study −0.70 −1.02 to -0.35 0.001 24%
Duration 8 weeks (vs 6 weeks) 0.10 −0.29 to 0.48 0.58 77%
Baseline MADRS score −0.11 −0.33 to 0.11 0.29 75%
Proportion of study participants non-White −0.04 −0.05 to -0.02 <0.001 0%
aPlacebo arm partitioned for multi-arm trial.
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10 mg) to a placebo group of 52.5 participants, of which
23.5 responded. Meta-regression of dose on the log odds
ratio of response was not statistically significant (β = 0.01;
P = 0.46). Meta-regression of dose on absolute change in
MADRS, without placebo arm partitioning, was also not
significant (β = 0.13; P = 0.09). Because of an apparent lack
of dose response, we pooled the dosing arms for the
remaining meta-regressions. Study quality, publication sta-
tus, or a combination of both (poor quality or unpublished)
had no impact on response. The only variables significantly
associated with response were whether or not the study
was conducted in the US (β = −0.7; P = 0.001) and the
proportion of study participants who were not White
(β = −0.04; P < 0.001). The later variable resulted in 0%
residual variation due to heterogeneity and is graphic-
ally depicted in Figure 5. Re-analyzing the studies by
the proportion of non-White participants (>20% non-
White, ≤20% non-White) eliminated nearly all statistical
heterogeneity between studies.
Adverse events
Table 3 summarizes pooled adverse event (AE) absolute
risk differences for each vortioxetine dose compared to
placebo. The most frequently reported AEs were nausea
and vomiting. At the 20-mg dose, 20.3% (95% CI 16.5%
to 24.2%) and 5.5% (95% CI 1.2% to 9.8%) more patients
treated with vortioxetine than placebo experienced nausea
and vomiting, respectively. The frequency of nausea in the
one trial evaluating the 1-mg dose (risk difference = 3.6%;
95% −2.0% to 9.2%) was similar to placebo, suggesting
there is an increase in nausea as the dose increases. With-
drawals due to an AE were significantly more common
than placebo at the 10-, 15-, and 20-mg doses, but not sig-
nificantly different for the 1-, 2.5-, and 5-mg doses. There
were no differences in the incidence of serious adverse
events.
Comparative efficacy
As shown in Figure 6, when compared to an SNRI (ven-
lafaxine extended release (XR) 225 mg or duloxetine60 mg), vortioxetine response was not statistically dif-
ferent for the 2.5-mg (RR = 0.89; 95% CI 0.76 to 1.04;
I2 = 2.5%) and 10-mg (RR = 0.98; 95% CI 0.86 to 1.11;
I2 = 0%) doses. Rates of response were significantly
lower than the SNRI for the 5-mg (RR = 0.88; 95% CI
0.80 to 0.98; I2 = 13%), 15-mg (RR = 0.78; 95% CI 0.68
to 0.90; I2 = 0%), and 20-mg (RR = 0.82; 95% CI 0.72 to
0.94; I2 = 0%) doses. Heterogeneity was low for all dose
comparisons. Removing the study which used venlafaxine
(Alvarez et al.) had no impact on treatment effect. As
shown in Figure 7, no dose of vortioxetine was statisti-
cally better, and the 5-mg dose was significantly worse
(RR = 0.81; 95% CI 0.66 to 0.999; I2 = 48%) than an SNRI
for achieving remission; however, heterogeneity was high
for several comparisons and pooled estimates may be
unreliable because of the small sample size. Figure 8
shows absolute change from baseline in MADRS score
for vortioxetine compared to an SNRI. Similar to re-
sponse, the 5-mg (−1.64; 95% CI −2.92 to −0.36; I2 = 19%),
15-mg (−3.42; 95% CI −5.13 to −1.71; I2 = 0%), and 20-mg
(−1.97; −3.68 to −0.27; I2 = 0%) doses were significantly
inferior to the SNRI comparator.Comparative adverse events
Comparative harms for vortioxetine relative to an SNRI
are summarized in Table 4. AEs generally occurred at a
lower frequency with vortioxetine than venlafaxine or
duloxetine. As the dose of vortioxetine was increased,
differences between vortioxetine and the SNRI were re-
duced. At the 20-mg dose, only hyperhidrosis was sig-
nificantly less common with vortioxetine. However,
discontinuation due to an AE was significantly higher
with vortioxetine 20 mg than the SNRI. Additional ana-
lyses are shown in Additional file 2.Publication bias
The funnel plots of response and remission shown in
Figures 9 and 10 do not suggest additional unpublished














0 10 20 30
Proportion non-White
Figure 5 Meta-regression plot showing relationship between proportion of non-White study participants and the log odds ratio for
response. Vortioxetine dose arms combined. β coefficient = −0.04 (95% CI −0.05 to −0.02).
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In this systematic review, we identified 11 studies that
evaluated response, remission, and change in baseline
depression scores of vortioxetine compared with placebo
or an SNRI in the treatment of MDD. Three of these
studies remain unpublished at the time of our analysis.
Two of the three unpublished studies did not show a
significant difference in response for any dosing arms
compared to placebo. Pooled treatment effect estimates
varied markedly between studies. There does not appear
to be a dose response when compared to placebo, sug-
gesting that doses as low as 5 mg may be as effective as
doses of 20 mg.
Vortioxetine does not appear to be more effective, and
is potentially less effective, than an SNRI. The SNRI com-
parator had significantly higher response rates compared
to vortioxetine 5-, 15-, and 20-mg doses. Significant differ-
ences in MADRS change from baseline relative to an
SNRI ranged from 1.64 for the 5-mg dose to 3.42 for the
15-mg dose. For remission, only the 5-mg vortioxetine
dose was significantly worse than an SNRI.
In terms of safety, at the FDA-recommended target
doses of 15 and 20 mg, the most common adverse effects
were nausea and vomiting occurring in about 20% (num-
ber needed to harm (NNH) = 5) and 5% (NNH= 20) more
patients receiving vortioxetine than placebo, respectively.
The 5-mg dose of vortioxetine was only associated with
an increased absolute risk of nausea and vomiting of 12%(NNH= 9) and 2% (NNH= 50), respectively. Rates of ser-
ious adverse events were similar at all dosing levels. When
compared to the SNRI group, vortioxetine generally had
lower rates of adverse events at the lower dose levels. At
the higher doses rates, adverse events were generally simi-
lar to an SNRI.
Variables significantly associated with response were
whether the study was conducted in the US and the pro-
portion of study participants who were White. Studies
with greater numbers of non-White participants (≥20%)
were consistently negative and studies with lower num-
bers of non-White participants were consistently positive.
This pattern roughly paralleled study location, where stud-
ies conducted within the US (Mahableshwarker et al., Jain
et al., NCT01153009, NCT01163266, NCT01179516) all
had a large (>20%) proportion of participants who were
non-white and were largely negative. It is unclear why
treatment effect differed by study site or racial compos-
ition. In their deliberations, the FDA recognized that effi-
cacy of vortioxetine was generally less favorable in studies
conducted in the US. In their review, the FDA deemed the
20-mg dose as the most consistently positive dosing arm
among US-based trials. The other four positive trials sup-
ported the efficacy of 5-, 10-, and 15-mg doses in at least
one trial, but were predominately non-US based. The final
product labeling reflects this interpretation by stating
“Dosage should then be increased to 20 mg/day, as toler-
ated, because higher doses demonstrated better treatment
Table 3 Absolute risk difference of adverse events for vortioxetine compared to placebo
1 mg 2.5 mg 5 mg 10 mg 15 mg 20 mg
Withdrawals due to adverse events 0.7% (−2.4%
to 3.8%) 1 trial
−0.6% (−4.3% to 3.1%);
I2 = 0% 2 trials
0.1% (−1.5% to 1.6%);
I2 = 1.6% 6 trials
1.9% (0.1% to 3.7%)*;
I2 = 0% 6 trials
4.4% (1.4% to 7.4%)*;
I2 = 0% 3 trials
3.6% (0.1% to 7.2%)*;
I2 = 58% 4 trials
Serious adverse events −0.7% (−3.1%
to 1.7%) 1 trial
−1.3% (−3% to 0.3%);
I2 = 0% 2 trials
0% (−1% to 1%);
I2 = 0% 6 trials
0% (−0.9% to 0.9%);
I2 = 0% 6 trials
0.1% (−0.9% to 1.0%);
I2 = 2% 3 trials
0.1% (−0.6% to 0.9%);
I2 = 0% 4 trials
Nausea 3.6% (−2.0%
to 9.2%) 1 trial
6.8% (1.4% to 12.1%)*;
I2 = 0% 2 trials
12.4% (8.9% to 15.9%)*;
I2 = 23% 6 trials
16.6% (11.1% to 22.2%)*;
I2 = 68% 6 trials
21.0% (15.9% to 26.1%)*;
I2 = 0% 3 trials
20.3% (16.5% to 24.2%)*;
I2 = 0% 4 trials
Vomiting not reported 0.1% (−1.6% to 1.8%);
I2 = 0% 2 trials
1.6% (0.1% to 3.1%)*;
I2 = 0% 4 trials
3.3% (0.8% to 5.9%)*;
I2 = 20% 4 trials
6.4% (0.7% to 12.1%)*;
I2 = 65% 2 trials
5.5% (1.2% to 9.8%)*;
I2 = 49% 2 trials
Headache −1.4% (−7.5%
to 4.6%) 1 trial
−0.1% (−5.6% to 5.4%);
I2 = 0% 2 trials
−0.5% (−4.2% to 3.2%);
I2 = 30% 6 trials
−0.5% (−3.3% to 2.4%);
I2 = 0% 6 trials
2.2% (−2.1% to 6.5%);
I2 = 0% 3 trials
4.1% (−0.7% to 7.5%);
I2 = 0% 4 trials
Diarrhea 0% (−2.8%
to 2.8%) 1 trial
−3.0% (−6.8% to 0.8%);
I2 = 0% 2 trials
0.3% (−2.5% to 3.1%);
I2 = 48% 6 trials
1.1% (−1.1% to 3.3%);
I2 = 0% 5 trials
3.7% (−1.5% to 8.8%);
I2 = 60% 3 trials
1.4% (−1.8% to 4.7%);
I2 = 0% 3 trials
Dizziness −1.4% (−4.2%
to 1.3%) 1 trial
−0.1% (−4.3% to 4.1%);
I2 = 24% 2 trials
−0.1% (−2.1% to 1.8%);
I2 = 0% 6 trials
−0.3% (−4.0% to 3.4%);
I2 = 56% 5 trials
1.3% (−4.4% to 7.0%);
I2 = 68% 3 trials
2.9% (−3.6% to 9.4%);
I2 = 76% 3 trials
Dry mouth −0.7% (−3.8%
to 2.4%) 1 trial
−0.3% (−7.3% to 6.7%);
I2 = 65% 2 trials
0.8% (−1.2% to 2.8%);
I2 = 0% 6 trials
−0.1% (−4.1% to 4.0%);
I2 = 64% 5 trials
−0.5% (−3.3% to 2.4%);
I2 = 0% 3 trials
0.6% (−4.9% to 6.1%);
I2 = 63% 3 trials
Hyperhydrosis −0.7% (−2.7%
to 1.3%) 1 trial
−0.0% (−1.6% to 1.6%);
I2 = 0% 2 trials
0.5% (−0.7% to 1.8%);
I2 = 0% 6 trials
2.4% (−1.2% to 6.0%);
I2 = 71% 3 trials
−1.0% (−3.2% to 1.1%);
I2 = 0% 2 trials
−1.8% (−5.6% to 2.0%);
I2 = 66% 2 trials
Nasopharyngitis −2.1% (−7.1%
to 2.8%) 1 trial
3.7% (−1.6% to 9.0%)
1 trial
0.7% (−1.2% to 2.5%);
I2 = 0% 4 trials
−0.7% (−2.5% to 1.2%);
I2 = 15% 6 trials
−2.7% (−5.8% to 0.4%);
I2 = 0% 2 trials
1.2% (−2.2% to 4.6%);
I2 = 48% 3 trials
Insomnia not reported 0.5% (−2.7% to 3.8%);
I2 = 0% 2 trials
−0.0% (−1.9% to 1.9%);
I2 = 0% 4 trials
−0.4% (−2.5% to 1.7%);
I2 = 0% 4 trials
0.1% (−2.9% to 3.2%);
I2 = 5% 2 trials
0.4% (−5.1% to 5.9%);
I2 = 64% 2 trials
Fatigue 2.1% (−0.6%
to 4.9%) 1 trial
−1.4% (−3.5% to 0.8%);
I2 = 0% 2 trials
0.4% (−1.4% to 2.2%);
I2 = 34% 6 trials
0.2% (−1.2% to 1.7%);
I2 = 0% 5 trials
0.5% (−2.2% to 3.2%);
I2 = 24% 3 trials
−0.8% (−5.8% to 4.2%);
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Figure 6 Forest plot showing response rates for vortioxetine by dose compared to a serotonin norepinephrine reuptake inhibitor.
Meeker et al. Systematic Reviews  (2015) 4:21 Page 11 of 16effects in trials conducted in the United States.” The FDA
review summarized several pooled subgroup analyses of
these six positive trials and found no variable to be statisti-
cally significant except region (non-US vs other) [20].
However, in their analysis of change from the baseline
MADRS score, the FDA note that White participants
tended to have larger treatment effects compared to Black
or Asian participants. It is important to note that whilethe clinical trial program for vortioxetine originally con-
sisted of ten controlled trials, only the six positive trials
were extensively analyzed for the application. The
remaining four negative or failed trials, which enrolled
higher numbers of non-White participants (21% to 29%
non-White), were not fully analyzed in the FDA’s review.
As such, their exclusion from the sponsor’s individual
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Figure 7 Forest plot showing remission rates for vortioxetine by dose compared to a serotonin norepinephrine reuptake inhibitor.
Meeker et al. Systematic Reviews  (2015) 4:21 Page 12 of 16deficiency, and further research is needed to understand
whether there is a difference in the efficacy of vortioxetine
in regards to diverse populations.
There are at least four limitations to this systematic
review. First, initial meta-analyses had significant hetero-
geneity. Although this was resolved by subgrouping trials
by racial composition, it is not clear if this variable is
truly an effect modifier. Vortioxetine is primarily metab-
olized through the cytochrome P450 2D6 enzyme, whichis known to vary between racial groups. However, the
FDA clinical pharmacology review concluded that race
did not have a significant impact on vortioxetine’s phar-
macokinetic profile [21]. As such, the observed associ-
ation between racial composition and response may be
due to some other unknown patient or study site charac-
teristic. A pharmacokinetic phase III study reviewed by
EMA found that non-quantifiable samples were signifi-
cantly more prevalent at US sites relative non-US sites,
Figure 8 Forest plot showing change from baseline in MADRS score for vortioxetine by dose compared to a serotonin norepinephrine
reuptake inhibitor.
Meeker et al. Systematic Reviews  (2015) 4:21 Page 13 of 16suggesting mediation adherence may have been a problem
[22]. Because race is a known predictor of medication
adherence, racial composition in our study may indicate
trials where compliance was poor [23]. A second import-
ant limitation is that our analysis relied on post hoc
standardized approaches to investigate potential reasons
for heterogeneity, including sensitivity analyses and meta-
regression, and therefore, their results should be inter-
preted with caution. The association between racial
composition and efficacy cannot be fully understood by
these analyses and should be studied in future work.Third, our analysis relies on aggregated summary data
rather than individual patient data (IPD), like most sys-
tematic reviews. A major advantage of IPD is the ability to
conduct subgroup analyses free of potential ecologic fal-
lacy. For this study, analysis of IPD could disentangle the
related issues of racial composition and geography, both
of which were associated with efficacy. Finally, trials were
short in duration (6 to 8 weeks) and limited to random-
ized controlled trials. Longer trials and non-randomized
trials, which can provide important information for asses-
sing harms, were not included in this analysis.
Table 4 Absolute risk difference of adverse events for vortioxetine compared to a serotonin norepinephrine reuptake inhibitor
1 mg 2.5 mg 5 mg 10 mg 15 mg 20 mg
Withdrawals due to
adverse events
No trials −6.2% (95% CI −10.7 to
−1.8%)*; I2 = 0% 2 trials
−4.7% (95% CI −9.0 to
−0.4%)*; I2 = 38% 4 trials
−4.4% (95% CI −9.7 to
0.9%); I2 = 0% 2 trials
2.3% (95% CI −1.7 to
6.3%); I2 = 0% 2 trials
4.4% (95% CI 0.1 to
8.7%)*; I2 = 0% 2 trials
Serious adverse events −1.0% (95% CI −2.5 to
0.6%); I2 = 0% 2 trials
0.1%(95% CI −1.1 to
1.3%); I2 = 0% 4 trials
0.4% (95% CI −1.6 to
2.4%); I2 = 0% 2 trials
−0.3% (95% CI −3.6 to
3.1%); I2 = 74% 2 trials
−0.1% (95% CI −1.3 to
1.1%); I2 = 0% 2 trials
Nausea −21.2% (95% CI −30.2 to
−12.3%); I2 = 42% 2 trials
−12.2% (95% CI −17.4 to
−7.0%); I2 = 0% 4 trials
−4.2% (95% CI −20.0
to 11.5%); I2 = 73% 2 trials
−2.8% (95% CI −10.3 to
4.7%); I2 = 73% 2 trials
−1.1% (95% CI −8.6 to
6.4%); I2 = 0% 2 trials
Vomiting −2.8% (95% CI −5.5 to
−0.1%)*; I2 = 0% 2 trials
−1.1% (95% CI −3.7 to
1.5%); I2 = 0% 3 trials
1.2% (95% CI −6.5 to
9.0%); I2 = 71% 2 trials
−3.2% (95% CI −8.8 to
2.3%) 1 trial
0.4% (95% CI −5.7 to
6.6%) 1 trials
Headache −0.3% (95% CI −5.8 to
5.2%); I2 = 0% 2 trials
−1.8% (95% CI −5.8 to
2.2%); I2 = 0% 4 trials
−2.1% (95% CI −8.5 to
4.3%); I2 = 0% 2 trials
−0.6% (95% CI −6.0 to
4.9%); I2 = 0% 2 trials
−1.8% (95% CI −9.0 to
5.5%); I2 = 43% 2 trials
Diarrhea −3.7% (95% CI −11.8 to
4.4%); I2 = 77% 2 trials
−1.8% (95% CI −5.0 to
1.4%); I2 = 26% 4 trials
1.5% (95% CI −2.4 to
5.3%); I2 = 0% 2 trials
−0.8% (95% CI −5.2 to
3.6%); I2 = 7% 2 trials
−1.6% (95% CI −7.6 to
4.4%); I2 = 46% 2 trials
Dizziness −9.9% (95% CI −14.7 to
−5.1%)*; I2 = 0% 2 trials
−7.0% (95% CI −12.5 to
−1.5%)*; I2 = 62% 4 trials
−9.1% (95% CI −15.7 to
−2.5%)*; I2 = 40% 2 trials
−5.7% (95% CI −10.3 to
−1.0)*; I2 = 0% 2 trials
−4.2% (95% CI −9.0 to
0.6%); I2 = 0% 2 trials
Dry mouth −9.5% (95% CI −22.7 to
3.8%); I2 = 86% 2 trials
−10.4% (95% CI −18.1 to
2.8%)*; I2 = 77% 4 trials
−5.2% (95% CI −9.8 to
−0.5%)*; I2 = 5% 2 trials
−6.8% (95% CI −11.3
to −2.3%)*; I2 = 0% 2 trials
−3.4% (95% CI −8.3 to
1.5%); I2 = 0% 2 trials
Hyperhydrosis −5.3% (95% CI −8.5 to
−2.2%)*; I2 = 0% 2 trials
−6.0% (95% CI −9.5 to
−2.6%)*; I2 = 35% 4 trials
−4.6% (95% CI −8.6 to
−0.6%)*; I2 = 0% 2 trials
−4.5% (95% CI −7.5 to
−1.4%)*; I2 = 0% 2 trials
−5.4% (95% CI −9.4 to
−1.4%)*; I2 = 43% 2 trials
Nasopharyngitis 5.8% (95% CI 1.1 to
10.5%)* 1 trial
4.6% (95% CI 1.0 to
8.3%)*; I2 = 0% 2 trials
1.4% (95% CI −1.6 to
4.3%); I2 = 0% 2 trials
0.7% (95% CI −3.6 to
5.0%) 1 trial
2.5% (95% CI −2.2 to
7.2%) 1 trial
Insomnia −3.3% (95% CI −7.1 to
0.5%); I2 = 0% 2 trials
−3.2% (95% CI −6.7 to
0.2%); I2 = 0% 3 trials
−6.4% (95% CI −10.5 to
−2.3%)*; I2 = 0% 2 trials
−5.9% (95% CI −11.4
to −0.4%)* 1 trial
−0.9% (95% CI −7.3 to
5.5%) 1 trial
Fatigue −5.3% (95% CI −8.3 to
−2.3%)*; I2 = 0% 2 trials
−4.7% (95% CI −7.3 to
−2.1%)*; I2 = 0% 4 trials
−3.3% (95% CI −6.9 to
0.3%); I2 = 0% 2 trials
−3.7% (95% CI −8.8 to
1.4%); I2 = 43% 2 trials
−3.6% (95% CI −7.6 to
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Figure 9 Funnel plot of response odds ratio for vortioxetine versus placebo. Vortioxetine dose arms combined.
Meeker et al. Systematic Reviews  (2015) 4:21 Page 15 of 16We purposely sought to identify and include all rele-
vant published and unpublished trials. To accomplish
this, we made use of the FDA website (Drugs@FDA.gov)
and the ClinicalTrials.gov result database as alternative
sources of summary trial data. The use of FDA medical
and statistical officer review documents has been recog-
nized as an important source of trial data for systematic
reviews [24]. In addition to FDA documents, we also
used summary results posted to ClinicalTrials.gov. Data
summarized in ClinicalTrials.gov were critical to incorp-
orating unpublished trial data as well as filling in the
gaps for outcomes that were either not reported or re-
ported ambiguously in the publication. ClinicalTrials.
gov was particularly useful for negative or failed trials,
because these trials are only briefly summarized by the
FDA [25]. Also, there was one trial in our review that
was not at all considered by the FDA [26]. Although
ClinicalTrials.gov result summaries have the potential
to be a great resource for complimenting systematic






















Figure 10 Funnel plot of remission odds ratio for vortioxetine versus[27-29]. With the inclusion of unpublished studies,
our funnel plot analyses did not suggest the presence
of other potentially unpublished trials. However, with
only 11 total trials, the power of these analyses was
limited [30].Conclusions
Similar to the FDA, we found that vortioxetine was sig-
nificantly more effective in response and remission than
placebo for acute treatment of MDD. However, our
study suggests that vortioxetine may not be more effect-
ive, and is potentially less effective, than an SNRI. We
found no evidence of a dose effect for vortioxetine with
the exception of adverse effects. The 20-mg dose was ap-
proved as the target dose by the FDA because it was the
only dose with at least two trials showing efficacy in the
US population. Our exploratory observation that studies
with higher non-white racial composition were less likely
to respond requires further study.Egger’s test p-value = 0.056
2 2.5 3
Odds Ratio
placebo. Vortioxetine dose arms combined.
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